RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIRâ"¢ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. In the study, WINREVAIR reduced the risk of clinical worseni. ...

格隆汇9月30日｜默克集团母公司E. Merck KG家族合伙人董事会近日宣布，任命Kai Beckmann接任默克 集团执行董事会主席暨首席执行官，自2026 年5 月1 日起生效。 ...

Just when the financial markets thought they had settled into a predictable rhythm of inflation worries and Federal Reserve tea leaves, President Donald J. Trump decided it was time for another impromptu policy concert. His recent barrage of tariff announcements and the perennial government shutdown theatrics have once again sent Wall Street scrambling to interpret the latest pronouncements from the Oval Office, proving that under this administration, the only constant is, well, *constant change*.The Tariff ...

We recently compiled a list of the 12 Most Undervalued Dow Stocks to Buy According to Analysts. Merck & Co., Inc. is one of them. Merck & Co., Inc. (NYSE:MRK) tops our list for being one of the most undervalued stocks. It is a global healthcare leader in pharmaceuticals, vaccines, biologics, and animal health products. A major recent development is the FDA approval of KEYTRUDA QLEX, a new subcutaneous injectable formulation of the company’s blockbuster cancer therapy Keytruda, on September 19, 2025. This ...

特朗普关税政策 - 宣布对进口软垫家具征收30%关税 对药品征收100%关税 对厨房橱柜和浴室盥洗台征收50%关税 对重型卡车征收25%关税 所有关税将于周三生效[1][2] - 关税政策以国家安全为由 但专家质疑厨房橱柜行业与赢得战争的必要性关联[3] - 美国财政部自2025财年以来征收1720亿美元关税 较2024财年同期增加960亿美元（增幅126%） 关税占联邦收入比例不足4%[5] 企业影响与应对 - Naturepedic公司从印度和越南进口软垫床头板 面临30%关税冲击 可能选择吸收成本或转嫁给消费者 甚至取消产品上市计划[1] - 药品制造商近年将业务转移至中国 印度（成本优势）及爱尔兰 瑞士（税收优惠） 100%药品关税旨在迫使企业将工厂迁回美国[7] - 家具价格过去一年上涨近10% 新关税可能进一步推高新房 公寓及装修项目成本[11][12] 行业与供应链反应 - 大型制药企业（默克 礼来 强生）已宣布美国扩张计划 100%关税不适用于已开工或在建企业 药品关税未提及仿制药（占处方药大多数）[9] - 家具 橱柜关税可能打击中国和越南等主要出口国 同时加剧零售供应链混乱 企业因政策不确定性难以规划缓解措施[11][13] - 重型卡车关税针对墨西哥制造（如帕卡集团旗下品牌） 可能为美墨加协定重新谈判施压[14][15] 政策法律背景 - 援引《1962年贸易扩展法》第232条对药品 木材 重型卡车启动国家安全调查 木材产品调查报告将于11月26日发布 或引发更广泛关税[11][16] - 此前依据《国际紧急经济权力法》征收关税被法院裁定越权 最高法院正在审理上诉案 第232条为关税政策提供备用法律路径[16][17]

股价表现 - 默克公司股价收于78.56美元 单日上涨1.24% 表现优于标普500指数0.59%的涨幅 道琼斯指数上涨0.65% 纳斯达克指数上涨0.44% [1] - 此前交易日公司股价累计下跌6.74% 同期医疗板块下跌0.94% 而标普500指数上涨2.72% [1] 财务预期 - 预计季度每股收益2.37美元 较去年同期大幅增长50.96% [2] - 预计季度营收171.9亿美元 同比增长3.18% [2] - 全年每股收益预期8.93美元 同比增长16.73% [3] - 全年营收预期649.4亿美元 同比增长1.21% [3] 估值指标 - 公司远期市盈率为8.69倍 显著低于行业平均的13.72倍 [6] - PEG比率为0.8倍 低于行业平均的1.5倍 显示估值相对盈利增长更具吸引力 [6] 分析师评级 - Zacks共识EPS预期在过去30天内保持稳定 [5] - 公司当前Zacks评级为3级(持有) [5] - 所属大型制药行业在Zacks行业排名中位列前35% 排名第85位(共250+行业) [7]

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

About four months have passed since my last article, "Merck Proves Why It's Still a Top Pharma Pick," and during that time, its stock price has risen by 5%.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investmen ...

About four months have passed since my last article, "Merck Proves Why It's Still a Top Pharma Pick," and during that time, its stock price has risen by 5%.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investmen ...

Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks in Goldman Sachs’ portfolio. On September 19, the company announced FDA approval for KEYTRUDA QLEX injection, the first subcutaneous version of its blockbuster cancer drug KEYTRUDA. Unlike the traditional intravenous (IV) form, QLEX can be administered subcutaneously (under the skin) in as little as one minute, providing patients and doctors with a faster and more convenient option. Merck’s (MRK) Oncology Portfolio Gets Shot in the Arm with QLEX ...